Palborest 125 (Palbociclib) is a medication used to treat certain types of breast cancer, including:
- Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer
- Hormone receptor-positive (HR+) and HER2-negative breast cancer that has progressed after treatment with other medications
Composition:
Palbociclib is a tablet formulation of Palbociclib, a selective inhibitor of cyclin-dependent kinases (CDKs).
Mechanism of Action:
Palbociclib works by inhibiting the activity of CDKs, which are proteins that help regulate cell growth and division. By inhibiting CDKs, Palbociclib can slow down the growth of cancer cells and prevent them from dividing.
Indications:
Palborest 125 (Palbociclib) is indicated for the treatment of:
- Hormone receptor-positive (HR+) and HER2-negative breast cancer in combination with letrozole in postmenopausal women
- Hormone receptor-positive (HR+) and HER2-negative breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
Dosage:
The recommended dosage of Palborest 125 is:
- 125 mg taken orally once daily, usually for 21 days, followed by a 7-day rest period
Side Effects:
Common side effects of Palborest 125 include:
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Muscle pain
- Joint pain
- Skin rash
- Hair loss
Contraindications:
Palborest 125 is contraindicated in patients who have a history of severe allergic reactions to the medication or who have had a severe reaction to a previous dose. Patients with certain medical conditions, such as liver problems or kidney problems, should also consult with their healthcare provider before taking Palborest 125.
Important Note:
Palborest 125 is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Patients should be advised to monitor their blood counts and liver function regularly during treatment.
Reviews
There are no reviews yet.